Insulet (PODD) vs Solventum (SOLV)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Solventum (SOLV) has outperformed Insulet (PODD) over the past year, gaining 1.9% versus a loss of 59.8%. Solventum is the larger company by market cap ($14.36 billion vs $9.24 billion), about 1.6 times the size, while Insulet is growing revenue faster (+30.7% vs +0.9%). On valuation, Solventum trades at a lower forward P/E (11.2x vs 16.8x for Insulet).
Solventum converts more of its revenue into profit, with a net margin of 18.7% versus 9.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PODD | SOLV |
|---|---|---|
| Share price | $133.17 | $84.50 |
| Market cap | $9.24B | $14.36B |
| 1-day change | -2.96% | -1.52% |
| YTD return | -53.15% | +6.64% |
| 1-year return | -59.79% | +1.93% |
| 5-year return | -54.92% | — |
| P/E ratio (TTM) | 21.76 | 94.94 |
| Forward P/E | 16.83 | 11.20 |
| EPS (TTM) | $6.12 | $0.89 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.71B | $8.32B |
| Revenue growth (YoY) | +30.73% | +0.86% |
| Net income (latest FY) | $247.10M | $1.56B |
| Gross margin | 71.63% | 53.47% |
| Operating margin | 17.50% | 26.20% |
| Net margin | 9.12% | 18.69% |
| 52-week high | $342.13 | $94.16 |
| 52-week low | $126.40 | $62.38 |
| Distance from 52-week high | -61.08% | -10.26% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +33.60% | +16.43% |
| Average volume | 1.61M | 1.03M |
| Shares outstanding | 69.37M | 169.96M |
| Employees | 5,400 | 20,584 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SOLV has outperformed PODD by 61.7 percentage points over the past year.
- Solventum trades at a higher earnings multiple (94.9x vs 21.8x trailing P/E).
- Solventum is more profitable, keeping 18.7 cents of every revenue dollar as net income versus 9.1 cents for Insulet.
- Insulet grew revenue faster in its latest fiscal year (+30.73% vs +0.86%).
About Insulet
PODD stock →Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System.
Health Care · Medical/Dental Instruments · 5,400 employees
About Solventum
SOLV stock →Solventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally. It operates through three segments: Medsurg, Dental Solutions, and Health Information Systems.
Health Care · Medical/Dental Instruments · 20,584 employees
PODD vs SOLV FAQ
Which is bigger, Insulet or Solventum?
Solventum (SOLV) is larger, with a market capitalization of $14.36B compared with $9.24B for Insulet (PODD).
Which stock has performed better over the past year, PODD or SOLV?
SOLV returned +1.93% over the past 12 months, compared with -59.79% for PODD (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, PODD or SOLV?
PODD has the lower trailing P/E at 21.8, versus 94.9 for SOLV. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Insulet and Solventum in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.